Literature DB >> 32134478

The Status of Vaccine Development Against the Human Cytomegalovirus.

Stanley A Plotkin1, Dai Wang2, Abdel Oualim3, Don J Diamond4, Camille N Kotton5, Sally Mossman6, Andrea Carfi7, David Anderson8, Philip R Dormitzer9.   

Abstract

Numerous candidate vaccines against cytomegalovirus (CMV) infection and disease are in development. Whereas the previous article [1] provides background and opinions about the issues relating to vaccination, this article provides specifics about the vaccines in active development, as reported at a National Institutes of Health-sponsored meeting in Bethesda on September 4-6, 2018. Here, vaccine developers provide synopses of their candidate vaccines to immunize women to protect against congenital CMV disease and to prevent the consequences of CMV disease in recipients of transplanted organs or hematopoietic stem calls. The projects are presented here roughly in the descending order of their stage of development in the opinion of the first author.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  cytomegalovirus; fetal infection; organ transplant; stem cell transplant

Year:  2020        PMID: 32134478      PMCID: PMC7057802          DOI: 10.1093/infdis/jiz447

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  44 in total

1.  Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.

Authors:  Corinna La Rosa; Jeff Longmate; Simon F Lacey; Teodora Kaltcheva; Rahul Sharan; Denise Marsano; Peter Kwon; Jennifer Drake; Brenda Williams; Sharon Denison; Suenell Broyer; Larry Couture; Ryotaro Nakamura; Sanjeet Dadwal; Morris I Kelsey; Arthur M Krieg; Don J Diamond; John A Zaia
Journal:  J Infect Dis       Date:  2012-03-07       Impact factor: 5.226

2.  Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin.

Authors:  Ashley E Fouts; Pamela Chan; Jean-Philippe Stephan; Richard Vandlen; Becket Feierbach
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

Review 3.  Prospects of a vaccine for the prevention of congenital cytomegalovirus disease.

Authors:  Bodo Plachter
Journal:  Med Microbiol Immunol       Date:  2016-08-12       Impact factor: 3.402

4.  Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.

Authors:  Mark R Schleiss; Ursula Berka; Elizabeth Watson; Mario Aistleithner; Bettina Kiefmann; Bastien Mangeat; Elizabeth C Swanson; Peter A Gillis; Nelmary Hernandez-Alvarado; Claudia Fernández-Alarcón; Jason C Zabeli; Daniel D Pinschewer; Anders E Lilja; Michael Schwendinger; Farshad Guirakhoo; Thomas P Monath; Klaus K Orlinger
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

5.  MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults.

Authors:  Corinna La Rosa; Jeff Longmate; Joy Martinez; Qiao Zhou; Teodora I Kaltcheva; Weimin Tsai; Jennifer Drake; Mary Carroll; Felix Wussow; Flavia Chiuppesi; Nicola Hardwick; Sanjeet Dadwal; Ibrahim Aldoss; Ryotaro Nakamura; John A Zaia; Don J Diamond
Journal:  Blood       Date:  2016-10-19       Impact factor: 22.113

6.  Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism.

Authors:  Dai Wang; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-30       Impact factor: 11.205

7.  Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.

Authors:  Shinu John; Olga Yuzhakov; Angela Woods; Jessica Deterling; Kimberly Hassett; Christine A Shaw; Giuseppe Ciaramella
Journal:  Vaccine       Date:  2018-02-15       Impact factor: 3.641

8.  Crystal Structure of the Human Cytomegalovirus Glycoprotein B.

Authors:  Heidi G Burke; Ekaterina E Heldwein
Journal:  PLoS Pathog       Date:  2015-10-20       Impact factor: 6.823

9.  Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial.

Authors:  Ryotaro Nakamura; Corinna La Rosa; Jeffrey Longmate; Jennifer Drake; Cynthia Slape; Qiao Zhou; Melanie G Lampa; Margaret O'Donnell; Ji-Lian Cai; Len Farol; Amandeep Salhotra; David S Snyder; Ibrahim Aldoss; Stephen J Forman; Jeffrey S Miller; John A Zaia; Don J Diamond
Journal:  Lancet Haematol       Date:  2015-12-24       Impact factor: 18.959

10.  Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines.

Authors:  Zhongde Wang; Joy Martinez; Wendi Zhou; Corinna La Rosa; Tumul Srivastava; Anindya Dasgupta; Ravindra Rawal; Zhongqui Li; William J Britt; Don Diamond
Journal:  Vaccine       Date:  2009-12-05       Impact factor: 3.641

View more
  18 in total

1.  A trimeric capable gB CMV vaccine provides limited protection against a highly cell associated and epithelial tropic strain of cytomegalovirus in guinea pigs.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  J Gen Virol       Date:  2021-03-17       Impact factor: 3.891

2.  Preventing Infection by Human Cytomegalovirus.

Authors:  Stanley A Plotkin
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

3.  A bivalent CMV vaccine formulated with human compatible TLR9 agonist CpG1018 elicits potent cellular and humoral immunity in HLA expressing mice.

Authors:  Vijayendra Dasari; Kirrilee Beckett; Shane Horsefield; George Ambalathingal; Rajiv Khanna
Journal:  PLoS Pathog       Date:  2022-06-23       Impact factor: 7.464

4.  Derisking Human Cytomegalovirus Vaccine Clinical Development in Relevant Preclinical Models.

Authors:  Sallie R Permar; Amitinder Kaur; Klaus Fruh
Journal:  J Infect Dis       Date:  2022-09-04       Impact factor: 7.759

Review 5.  Vaccines for Perinatal and Congenital Infections-How Close Are We?

Authors:  Tulika Singh; Claire E Otero; Katherine Li; Sarah M Valencia; Ashley N Nelson; Sallie R Permar
Journal:  Front Pediatr       Date:  2020-12-15       Impact factor: 3.418

Review 6.  NK Cell Memory to Cytomegalovirus: Implications for Vaccine Development.

Authors:  Calum Forrest; Ariane Gomes; Matthew Reeves; Victoria Male
Journal:  Vaccines (Basel)       Date:  2020-07-20

7.  Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion.

Authors:  Yuhang Liu; Kyle P Heim; Ye Che; Xiaoyuan Chi; Xiayang Qiu; Seungil Han; Philip R Dormitzer; Xinzhen Yang
Journal:  Sci Adv       Date:  2021-03-05       Impact factor: 14.136

8.  The Incidence and Effect of Cytomegalovirus Disease on Mortality in Transplant Recipients and General Population: Real-world Nationwide Cohort Data.

Authors:  Sang Hoon Han; Seul Gi Yoo; Kyung Do Han; Yeonju La; Da Eun Kwon; Kyoung Hwa Lee
Journal:  Int J Med Sci       Date:  2021-07-25       Impact factor: 3.738

Review 9.  Understanding the interaction between cytomegalovirus and tuberculosis in children: The way forward.

Authors:  Laura Olbrich; Lisa Stockdale; Robindra Basu Roy; Rinn Song; Luka Cicin-Sain; Elizabeth Whittaker; Andrew J Prendergast; Helen Fletcher; James A Seddon
Journal:  PLoS Pathog       Date:  2021-12-09       Impact factor: 6.823

10.  Exciting Times for Cytomegalovirus (CMV) Vaccine Development: Navigating the Pathways toward the Goal of Protecting Infants against Congenital CMV Infection.

Authors:  Mark R Schleiss; Don J Diamond
Journal:  Vaccines (Basel)       Date:  2020-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.